# A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01202188** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 2144 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** indacaterol and glycopyrronium (QVA149)
- **DRUG:** glycopyrronium (NVA237)
- **DRUG:** indacaterol (QAB149)
- **DRUG:** tiotropium
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01202188
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2012-02
- **Final completion:** 2012-03
- **Target enrollment:** 2144 (ACTUAL)
- **Last updated:** 2013-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01202188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01202188, "A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01202188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*